as introduced - 92nd Legislature (2021 - 2022) Posted on 03/08/2021 02:24pm
A bill for an act
relating to health; authorizing incentives for manufacturers that choose to import
certain drugs pursuant to "Pathway 2" of the safe importation action plan; proposing
coding for new law in Minnesota Statutes, chapter 62J.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:
new text begin
(a) For purposes of this section, the following terms have
the meanings given.
new text end
new text begin
(b) "Drug product" or "drug" means a prescription drug or biological product that is
intended for human use and regulated as a drug except where specific reference is made to
a drug approved under section 505 of the federal Food, Drug, and Cosmetic Act, United
States Code, title 21, section 355, or biological product approved under section 351 of the
federal Public Health Act, United States Code, title 42, section 262. Drug product or drug
does not include biological products that are intended for transfusions, including blood or
blood products; or allogeneic-, cellular-, or tissue-based products.
new text end
new text begin
(c) "FD&C Act" means the federal Food, Drug, and Cosmetic Act, United States Code,
title 21, section 301, et seq.
new text end
new text begin
(d) "Importation guidance" means the draft guidance released by the FDA titled
"Importation of Certain FDA-Approved Human Prescription Drugs, Including Biological
Products, Under Section 801(d)(1)(B) of the Federal Food, Drug, and Cosmetic Act; Draft
Guidance for the Industry," which if finalized allows for the importation of MMA products.
new text end
new text begin
(e) "Manufacturer" means the entity that is the holder of the New Drug Application or
Biologics License Application for the drug product.
new text end
new text begin
(f) "Multimarket-approved product" or "MMA product" means a federal Food and Drug
Administration (FDA)-approved drug product that:
new text end
new text begin
(1) was manufactured outside the United States and authorized for marketing by another
country's regulatory authority;
new text end
new text begin
(2) is subject to a new drug application or biologics license application;
new text end
new text begin
(3) is imported into the United States and is authorized by the manufacturer to be
marketed in the United States; and
new text end
new text begin
(4) continues to meet the quality standards for marketing in its originally intended foreign
market.
new text end
new text begin
This section applies to any MMA product in which the
manufacturer of the product has obtained a new National Drug Code (NDC) for the MMA
product and has imported the MMA product in compliance with the FD&C Act and any
importation guidance finalized by the FDA.
new text end
new text begin
(a) In order to facilitate importation of drugs pursuant to importation
guidance finalized by the FDA, any MMA product offered for sale in Minnesota at a cost
that is at least 23 percent lower than the wholesale acquisition cost for the FDA-approved
product manufactured in the United States shall be:
new text end
new text begin
(1) included on the uniform preferred drug list and covered under the medical assistance
and MinnesotaCare programs; and
new text end
new text begin
(2) a covered drug under the state employee group insurance program pursuant to chapter
43A.
new text end
new text begin
(b) A health plan company must provide coverage for each MMA product that meets
the requirements in paragraph (a) if the manufacturer's FDA-approved drug product
manufactured in the United States is covered by the health plan company and the health
plan company must not impose any enrollee cost-sharing requirements for the covered
MMA product.
new text end
new text begin
(c) This subdivision shall not become effective for MMA products that are offered for
sale in Minnesota in accordance with paragraph (a) unless affirmative action is taken by
the legislature.
new text end